PCM
APLS

Peregrine Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Peregrine Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-114,533
Closed -$3.3M – 333
2024
Q3 		$3.3M Buy
114,533
+254
+0.2% +$9.41K 0.1% 244
2024
Q2 		$4.38M Buy
114,279
+21,619
+23% +$979K 0.13% 239
2024
Q1 		$5.45M Buy
+92,660
New +$5.91M 0.16% 226

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Peregrine Capital Management's APLS Position: Q4 2024 in Review

Peregrine Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 114,533 shares — an estimated $3.3M sold.

Peregrine Capital Management first reported a position in APLS in Q1 2024 and held it in 3 quarters. The position peaked at $5.45M in Q1 2024. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Peregrine Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Peregrine Capital Management sold 114,533 Apellis Pharmaceuticals shares in Q4 2024, an estimated $3.3M.
  • Peregrine Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Peregrine Capital Management's Apellis Pharmaceuticals position peaked at $5.45M in Q1 2024.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Peregrine Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.